Vaxcyte Misses Q1 Estimates as Net Loss Widens to $320.6 Million
PCVX has more than doubled off its 52-week low of $28.09.
Summary
Vaxcyte reported a Q1 net loss of $320.62 million, significantly wider than the $256.39 million analyst consensus, indicating a substantial miss on expectations. Operating expenses rose to $345.85 million, primarily driven by increased research and development and product manufacturing costs for its vaccine programs. This financial update follows an 8-K filed earlier today which focused on the completion of enrollment for VAX-31 adult Phase 3 and infant Phase 2 trials, but did not detail Q1 financial performance. The widening loss and higher-than-expected burn rate, despite a strong cash position of $2.7 billion, are material and likely to put negative pressure on the stock. Investors will now closely monitor the upcoming clinical trial data, with OPUS-1 Phase 3 topline data expected in Q4 2026 and OPUS-2/OPUS-3 results in the first half of 2027, as these will be critical catalysts for future valuation.
At the time of this announcement, PCVX was trading at $57.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $28.09 to $65.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.